RGD Reference Report - Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer.

Authors: Akahira, JI  Aoki, M  Suzuki, T  Moriya, T  Niikura, H  Ito, K  Inoue, S  Okamura, K  Sasano, H  Yaegashi, N 
Citation: Akahira JI, etal., Br J Cancer. 2004 Jun 1;90(11):2197-202.
RGD ID: 2289854
Pubmed: PMID:15164121   (View Abstract at PubMed)
PMCID: PMC2409481   (View Article at PubMed Central)
DOI: DOI:10.1038/sj.bjc.6601832   (Journal Full-text)

Oestrogen receptor-binding fragment associated gene 9, EBAG9, is an oestrogen-responsive gene that was identified in MCF-7 human breast carcinoma cell line. It is identical to RCAS 1, a cancer cell surface antigen possibly involved in immune escape. In the present study, we examined the expression of EBAG9/RCAS1 in human epithelial ovarian cancer using immunohistochemistry, immunoblotting and reverse transcription-polymerase chain reaction (RT-PCR). A total of 90 epithelial ovarian cancer cases were examined immunohistochemically by means of the antibodies for EBAG9 and ERalpha. The correlation between EBAG9 immunoreactivity and clinicopathological parameters was examined. mRNA expression of EBAG9 and ERalpha were evaluated by RT-PCR in 22 cases. The expression for EBAG9 and ERalpha was examined by immunoblotting in 12 ovarian cancer cell lines. EBAG9 immunoreactivity was detected in the surface and cytoplasm of carcinoma cells in 46 out of 90 cases (51.1%). EBAG9 expression was significantly higher in serous histology (P=0.0402) and advanced disease (P=0.0206). No significant relationship was detected between EBAG9 immunoreactivity and overall survival (P=0.689). There was a highly significant correlation between EBAG9 and ER immunoreactivity (P<0.0001). The EBAG9 mRNA was detected in 20 out of 22 cases. In all of the cases that were positive for ERalpha mRNA, they were also positive for EBAG9 mRNA. Immunoreactive band corresponding to EBAG9 was detected in 11 out of 12 of ovarian cancer cell lines, and was consistent with ERalpha expression. In conclusion, the wide distribution of EBAG9 and its relation to advanced disease suggest that this protein may play important roles in epithelial ovarian cancer.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
ovarian cancer disease_progressionIEP 2289854protein:increased expression:ovaryRGD 
ovarian cancer disease_progressionISOEBAG9 (Homo sapiens)2289854; 2289854protein:increased expression:ovaryRGD 

Objects Annotated

Genes (Rattus norvegicus)
Ebag9  (estrogen receptor binding site associated antigen 9)

Genes (Mus musculus)
Ebag9  (estrogen receptor-binding fragment-associated gene 9)

Genes (Homo sapiens)
EBAG9  (estrogen receptor binding site associated antigen 9)


Additional Information